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Mild renal insufficiency is associated with increased left ventric-
ular mass in men, but not in women: An arterial stiffness–related
phenomenon—The Hoorn Study.
Background. Mild renal insufficiency has recently been rec-
ognized as an important risk factor for cardiovascular disease
(CVD). The mechanisms underlying this association are incom-
pletely understood. Increased left ventricular mass (LVM) is an
independent risk factor for CVD, which is particularly common
in end-stage renal disease (ESRD) and which has been shown
to be associated with mild renal insufficiency. Increased arterial
stiffness has also been shown to be an independent risk factor
for CVD in ESRD and has also been associated with mild re-
nal insufficiency. We hypothesized that the association between
mild renal insufficiency and increased LVM could be mediated
through increased arterial stiffness, and that this may be one of
the pathways linking mild renal insufficiency to CVD. We there-
fore investigated, in a cross-sectional population-based study,
the influence of increased arterial stiffness on the association
between renal function and LVM.
Methods. The study population consisted of 742 elderly
individuals (373 men and 369 women). Renal function was esti-
mated by the serum creatinine level in lmol/L; by the Cockcroft-
Gault formula in mL/min and by the Modification of Diet in
Renal Disease (MDRD) formula. LVM was obtained by
echocardiography.
Results. The mean estimates of renal function in men and
women were, respectively, 103.7 (SD 17.0) and 86.8 (SD 11.2)
lmol/L for the serum creatinine level; 63.4 (SD 12.9) and 61.4
(SD 11.0) mL/min/1.73 m2 for the Cockcroft-Gault formula; and
59.7 (SD 10.8) and 60.9 (SD 10.5) mL/min per 1.73 m2 for the
MDRD formula. LVM was 93.1 (SD 26.4) g/m2 in men and 86.7
(SD 22.3) g/m2 in women. In men, impaired renal function, as
estimated by the Cockcroft-Gault and the MDRD formula, was
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significantly associated with greater LVM after adjustment for
age, glucose tolerance, hypertension, and prior CVD [regres-
sion coefficient b (95% CI), 1.28 (0.22 to 2.33) g/m2 and 1.63
(0.41 to 2.86) g/m2 per 5 mL/min/1.73 m2 decrease, respectively].
However, the association between impaired renal function and
increased LVM was not statistically significant after adjustment
for arterial stiffness estimates [regression coefficient b (95%
CI), 0.02 (−1.60 to 1.64) g/m2 and 0.54 (−1.25 to 2.33) g/m2 per
5 mL/min/1.73 m2 decrease, respectively]. In women, impaired
renal function was not significantly associated with greater
LVM.
Conclusion. Our study shows that in a general elderly popu-
lation, even mild impairment of renal function is associated with
adverse changes in left ventricular structure. In men, but not in
women, this leads to greater LVM, a process that may be re-
lated to increases in arterial stiffness. Importantly, these novel
findings suggest that such changes occur early in the process
of renal functional deterioration, which may explain, in part,
the increase in cardiovascular risk in men with mildly impaired
renal function.
Mild renal insufficiency has recently been recognized
as an important risk factor for cardiovascular disease
(CVD) and mortality [1–4]. The mechanisms underlying
this association are incompletely understood. In a previ-
ous study, we have shown that a decrease in glomeru-
lar filtration rate (GFR) from 90 to 60 mL/min/1.73
m2 in a population-based setting was associated with a
fourfold increase in risk of cardiovascular mortality, and
that this was independent of both traditional risk factors
(e.g., hypertension and prior cardiovascular disease) and
nontraditional risk factors (e.g., markers of endothelial
dysfunction and chronic, low-grade inflammation, and
homocysteine level) [3].
Increased left ventricular mass (LVM) is an indepen-
dent risk factor for CVD, which is particularly common
in end-stage renal disease (ESRD) and which has been
shown to be associated with mild renal insufficiency [1,
5–9]. Increased LVM is thought to increase CVD risk
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through a series of unfavorable metabolic, functional,
and structural cardiac changes [10–13], thus increasing
the risk of myocardial infarction, heart failure, ventricu-
lar arrhythmia, and sudden death [8].
Increased arterial stiffness has also been shown to be
an independent risk factor for CVD in ESRD and has
been shown to be associated mild renal insufficiency [14–
19]. Increased arterial stiffness could lead to increased
CVD morbidity and mortality via similar phenomena as
increased LVM. However, the influence of increased arte-
rial stiffness on the association between mild renal insuf-
ficiency and increased LVM has not been investigated.
We hypothesized that the association between mild re-
nal insufficiency and increased LVM could be mediated
through increased arterial stiffness, and that this may be
one of the pathways linking mild renal insufficiency to
cardiovascular morbidity and mortality. To test this hy-
pothesis, we investigated, in a cross-sectional population-
based cohort of 742 individuals, the association between
renal function [as estimated from serum creatinine, the
Cockcroft-Gault formula, and the Modification of Diet in
Renal Disease (MDRD) formula [3, 20]] and LVM. In ad-
dition, we explored whether any such associations could
be explained by, on the one hand, traditional CVD risk
factors, such as hypertension, or on the other hand, by
increased arterial stiffness, a novel risk factor for CVD,
which often accompanies impaired renal function [14–
19].
METHODS
Study population
For the present cross-sectional investigation, we used
data from the 2000 Hoorn Study follow-up examination
[21, 22] and the Hoorn Screening Study [23]. Details and
sampling procedures have been detailed elsewhere [22,
23]. Briefly, the Hoorn Study is a cohort study of glucose
tolerance in the general population (N = 2484), which
started in 1989 [21]. In 2000, a follow-up examination was
carried out among all participants who had given their
permission to be recontacted. We invited all those who
were diagnosed as having diabetes at the previous 1996
follow-up examination (N = 176) and random samples
of individuals with normal glucose metabolism (N = 705)
and impaired glucose metabolism (N = 193). Of the 1074
individuals thus invited, 648 (60%) participated. In ad-
dition, we invited 217 individuals with diabetes mellitus
type 2 from the Hoorn Screening Study, a population-
based targeted type 2 diabetes screening study [23], of
whom 188 (87%) participated. Among the 455 nonpar-
ticipants (53% women), 13% were complete nonrespon-
ders. The remaining nonparticipants gave, by telephone
interview, various reasons not to participate: lack of inter-
est (30%), comorbidity (23%), age (7%), unwillingness
to travel (6%), participation too time-consuming (6%),
and miscellaneous reasons (15%).
The local ethics committee approved the study and
written informed consent was obtained from all par-
ticipants. Each participant underwent an oral glucose
tolerance test, except those with previously diagnosed
diabetes (N = 67), and was classified according to the
1999 World Health Organization (WHO) criteria [24].
The final study population consisted of 822 individuals
(290 with normal glucose metabolism, 187 with interme-
diate glucose metabolism, and 345 with type 2 diabetes
mellitus), as data on 14 individuals were missing.
Estimates of renal function
Renal function was estimated by the serum creati-
nine level in lmol/L; by the Cockcroft-Gault formula in
mL/min ([140 – age] ∗ body weight/[creatinine ∗ 72] ∗ 0.85
if female); and by the MDRD formula (Levey’s equa-
tion) in mL/min (170 ∗ [creatinine]−0.999 ∗ [age]−0.176 ∗
[urea]−0.170 ∗ [albumin]+0.318 ∗ 0.762 if female) [13]. The
Cockroft-Gault and MDRD formulas were both ex-
pressed per 1.73 m2 body surface area [25]. Formulas are
given in traditional units. To convert to International Sys-
tem units multiply creatinine in mg/dL by 88.4, urea in
mg/dL by 0.357, and albumin in g/dL by 10.
Echocardiography
An experienced research technician unaware of the
participants’ clinical or glucose tolerance status obtained
an echocardiogram in each participant, according to a
standardized protocol, with the use of a single ultrasound
scanner (HP SONOS 5500) (Andover, MA, USA). M-
mode recordings were digitally stored and read according
to the guidelines of the American Society of Echocardio-
graphy [26, 27].
Left ventricular end-diastolic diameter (EDD), poste-
rior wall thickness (PWT), and the interventricular sep-
tum thickness (IVS) were measured at end diastole. LVM
was calculated as 0.8 (1.04) [(EDD + IVS + PWT)3 −
EDD3] + 0.6 divided by body surface area in g/m2 and rel-
ative wall thickness (RWT) as (IVS + PWT)/EDD [27].
Each echocardiogram was inspected afterwards by a se-
nior cardiologist blinded to the participants’ clinical or
glucose tolerance status to monitor the quality of both
recordings and readings.
Left ventricular geometric patterns were classified ac-
cording to Heesen et al [28].
Arterial stiffness
We measured carotid and femoral artery distensibil-
ity and compliance coefficients; total systemic arterial
compliance; the height-adjusted carotid-femoral transit
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time, a surrogate for carotid-femoral pulse wave velocity
(PWV); and the aortic augmentation index, as previously
described in detail [22, 29]. The distensibility and com-
pliance coefficient reflect elastic properties and buffer-
ing capacity, respectively [30]. Total systemic arterial
compliance reflects the overall buffering capacity of the
arterial system, mainly of the proximal aorta [29].
Carotid-femoral transit time estimates the average aortic
distensibility or bulk modulus K (K = PWV2 ( q, where q
is blood viscosity). This method assumes a uniform aorta
and gives compliance of mainly the descending aorta. The
aortic augmentation index depends on timing of the re-
flected waves, and thus on PWV, as well as on the mag-
nitude and location of reflection sites, and is therefore a
less pure estimate of arterial stiffness [29].
Other measurements
Health status, medical history, current medication use,
and smoking habits were assessed by a questionnaire [21,
23]. We determined systolic and diastolic pressure, mean
arterial pressure, pulse pressure, hypertension (defined
as systolic pressure ≥ 140 mm Hg and diastolic pressure
≥ 90 mm Hg and/or the current use of antihypertensive
medication), glucose, glycated hemoglobin, insulin, ho-
mocysteine, serum total, high-density and low-density-
lipoprotein cholesterol, serum triglycerides, body mass
index, waist-to-hip ratio, and ankle-brachial pressure in-
dex as described elsewhere [22, 23, 31].
Resting electrocardiograms were automatically coded
according to the Minnesota Code [32]. Prior CVD was
defined as Minnesota Code 1.1-1.3, 4.1-4.3, 5.1-5.3, or 7.1
on the electrocardiogram or coronary bypass operation
or angioplasty, or an ankle-brachial blood pressure in-
dex <0.9 in either leg, or peripheral arterial bypass, or
amputation for atherosclerotic disease.
Statistical analyses
All analyses were performed using SPSS 10.1 for Win-
dows 98. We used multiple linear regression analysis to
investigate the associations between the estimates of re-
nal function (determinants) and left ventricular structure
(outcomes). All associations were first analyzed without
adjustments (crude model) and then with adjustment for
potential confounders (adjusted models). We analyzed
men and women separately, because there may be impor-
tant gender differences in the determinants of LVM [33–
37]. Statistically this gender difference was confirmed by
the results of our interaction analyses (gender ∗ estimate
of renal function) in which all interaction terms were ≤
0.005. As left ventricular structure is known to be affected
by age and glucose tolerance status [38–42], these vari-
ables were considered first in the adjusted models (age
was omitted from the models with the Cockcroft-Gault
and MDRD formula because of its incorporation in both
formulas). We then added potential confounding or me-
diating variables to the models [i.e., hypertension, prior
cardiovascular disease, (micro-) albuminuria, homocys-
teine, and arterial compliance). Results are described as
regression coefficients (b) with 95% CI per a 5 unit in-
crease for serum creatinine level and per a 5 unit decrease
for both the Cockcroft-Gault and MDRD formula.
Diabetes and hypertension are often accompanied by
impaired renal function. We therefore used interaction
terms to investigate whether the association between es-
timates of renal function and left ventricular structure
differed according to the presence of diabetes and hyper-
tension, because any such interactions might be clinically
important.
P values < 0.05 were considered statistically significant,
except for the interaction analyses where we used < 0.10
as cutoff value.
RESULTS
In 42 of the 822 participants, LVM could not be deter-
mined due to either a high body mass index (N = 33; body
mass index of those with qualitatively satisfactory exam-
inations versus those without, 27.5 ± 3.8 kg/m2 versus
37.9 ± 8.9 kg/m2 (P < 0.001) or a poor transthoracic
window (N = 9). In the remaining 780 individuals all
three estimates of renal function could be determined in
742 individuals because of (randomly) missing laboratory
values.
Clinical characteristics
The mean serum creatinine level was 103.7 (SD 17.0)
lmol/L in men and 86.8 (SD 11.2) lmol/L in women
(Table 1). Mean creatinine clearance, as estimated
by the Cockcroft-Gault formula, was 63.4 (SD 12.9)
mL/min/1.73 m2 in men and 61.4 (SD 11.0) mL/min/ 1.73
m2 in women. Mean glomerular filtration rate (GFR),
as estimated by the MDRD formula, was 59.7 (SD 10.8)
mL/min per 1.73 m2 in men and 60.9 (SD 10.5) mL/min
per 1.73 m2 in women. LVM was 93.1 (SD 26.4) g/m2 in
men and 86.7 (SD 22.3) g/m2 in women.
Associations between estimates of renal function
and LVM
In men, impaired renal function, as estimated by the
Cockcroft-Gault and the MDRD formula, was signifi-
cantly associated with greater LVM after adjustment for
age, glucose tolerance, hypertension and prior cardiovas-
cular disease (regression coefficient b (95% CI), 1.28
(0.22 to 2.33) g/m2 and 1.63 (0.41 to 2.86) g/m2 per 5
mL/min/1.73 m2 decrease, respectively (Table 2, model 4).
Additional adjustment for (micro-) albuminuria or
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Table 1. Clinical characteristics of the study population
Men Women
(N = 373) (N = 369)
Age years 68.2 ± 7.3 69.1 ± 6.7
Fasting glucose mmol/L 6.5 ± 1.6 6.4 ± 1.4
Postload glucose mmol/L 7.0 ± 2.6 7.3 ± 2.6
Glycated hemoglobin% 6.1 ± 0.8 6.1 ± 0.7
Fasting insulin pmol/L 59.5 (43.0–85.0) 61.0 (43.0-91)
Body mass index kg/m2 27.3 ± 3.3 27.6 ± 4.0
Waist-to-hip ratio 0.98 ± 0.07 0.88 ± 0.09a
Total cholesterol mmol/L 5.4 ± 1.0 6.0 ± 1.0a
Low-density lipoprotein
cholesterol mmol/L
3.4 ± 0.9 3.8 ± 0.9a
High-density lipoprotein
cholesterol mmol/L
1.2 ± 0.3 1.6 ± 0.4a
Triglycerides mmol/L 1.3 (1.0–1.9) 1.3 (1.0-1.8)
Lipid-lowering medication% 18 15
Systolic pressure mm Hg 140 ± 17 146 ± 22a
Diastolic pressure mm Hg 78 ± 9 77 ± 9
Mean arterial pressure mm Hg 99 ± 11 100 ± 13
Hypertension% 68 70
Antihypertensive medication% 36 40
Arterial stiffness
Carotid distensibility
10−3.kPa−1
12.1 ± 4.3 11.0 ± 4.5a
Carotid compliance mm2.kPa−1 0.64 ± 0.24 0.48 ± 0.17a
Femoral distensibility
10−3.kPa−1
4.6 ± 2.1 4.8 ± 2.2
Femoral compliance
mm2.kPa−1
0.40 ± 0.20 0.33 ± 0.40a
Carotid-femoral transit timeb
msec
56.8 ± 16.9 51.7 ± 15.1a
Total systemic arterial
compliance mL/mm Hg
0.90 ± 0.29 1.16 ± 0.32a
Aortic augmentation index% 29.8 ± 8.9 35.5 ± 7.4a
Prior cardiovascular disease% 47 48
Smoking% 18 12a
(Micro-) albuminuria% 17 12a
Homocysteine lmol/L 12.4 ± 4.51 11.0 ± 3.41a
Renal function estimate
Serum creatinine level lmol/L 103.7 ± 17.0 86.8 ± 11.2a
Cockcroft-Gault formula
mL/min/1.73 m2
63.4 ± 12.9 61.4 ± 11.0a
MDRD formula (GFR)
mL/min/1.73 m2
59.7 ± 10.8 60.9 ± 10.5c
Measurements of left ventricular
structure
Mass g/m2 93.1 ± 26.4 86.7 ± 22.3a
End diastolic diameter cm 5.24 ± 0.59 4.90 ± 0.52a
Posterior wall thickness cm 0.93 ± 0.15 0.88 ± 0.15a
Interventricular septum
thickness cm
1.01 ± 0.24 0.96 ± 0.23a
Relative wall thickness 0.38 ± 0.09 0.38 ± 0.09
MDRD is Modification of Diet in Renal Disease; GFR is glomerular filtration
rate. Results are expressed as mean ± standard deviation, percentage or median
(interquartile range). Measurements of left ventricular structure were derived
from M-mode.
aP value for difference < 0.05.
bAdjusted for height; available in 151 in men and 148 women. Total systemic
arterial compliance as estimated by statistical values divided by local pulse
pressure (see the Methods section).
cP value for difference < 0.1.
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homocysteine somewhat decreased the associations
(Table 2, models 5 and 6, respectively). However, the as-
sociation between impaired renal function and increased
LVM decreased substantially, and was not statistically sig-
nificant, after adjustment for arterial stiffness estimates
(Table 2, models 7b to d). In women, impaired renal func-
tion was not significantly associated with greater LVM
(Table 2, models 1 to 6). The P values for interaction
(gender ∗ estimate of renal function) were ≤ 0.005.
Renal function and left ventricular structure
and geometry
Table 3 and Figure 1 show that the percentage of men
with normal left ventricular geometry decreased signifi-
cantly with lower GFR, whereas the percentage of men
with left ventricular remodeling or hypertrophy increased
significantly [P value for overall linear-by-linear associa-
tion over categories of GFR and left ventricular geomet-
ric patter (N = 0.002)].
In women, lower GFR was not significantly associated
with left ventricular geometry (Table 3) [P value for over-
all linear-by-linear association over categories of GFR
and left ventricular geometric patter (N = 0.51)].
Table 2 shows that, in men, impaired renal function was
significantly associated with greater LVM, but does not
provide insight into the role of the individual elements
of the formula for LVM. Table 4 shows that, after ad-
justment for age, glucose tolerance, hypertension, prior
CVD and (micro-) albuminuria, lower GFR was signif-
icantly associated with greater PWT [b per 5 mL/min/
1.73 m2 decrease, 0.014 cm (0.004 to 0.024)], IVS [b , 0.024
cm (0.014 to 0.033)], and RWT [b , 0.007 (0.002 to 0.011)].
In women a similar pattern was seen. Further analyses
showed that the correlation coefficient between PWT
and IVS was 0.71 in men and 0.51 in women (P value
for both < 0.001). This difference may explain why the
associations between lower GFR and altered left ventric-
ular structure were similar in men and women (Table 4),
while the association between lower GFR and greater
LVM was seen only in men (Table 2).
Additional analyses
Additional adjustment for body mass index, waist-to-
hip ratio, insulin, lipid profile, smoking, heart rate, or
the use of lipid-lowering or antihypertensive medica-
tion [including angiotensin-converting enzyme (ACE) in-
hibitors] did not materially alter our results stiffness (data
not shown). Results were also not materially altered if
we repeated the analyses with any of the other measure-
ments of arterial stiffness (data not shown). Results were
not altered if we excluded individuals with left ventricular
wall motion abnormalities (N = 49) (11 women) and/or
those with GFR < 30 mL/min1.73 m2 as estimated by the
MDRD formula (N = 5) (2 women). In addition, these
results did not differ according to the presence of hyper-
tension or diabetes (P values for interaction both > 0.16)
(data not shown).
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Table 2. Associations between estimates of renal function and left ventricular mass in men and women
Men WomenDependent Variable
Left ventricular Serum Cockcroft-Gault MDRD Serum Cockcroft-Gault MDRD
mass g/m2 creatinine level formulaa formulaa creatinine level formulaa formulaa
Model Added Variables
1 Crude 1.05 1.58 1.98 0.40 0.75 0.23
(0.26; 1.84) (0.53; 2.62) (0.72; 3.24) (−0.63; 1.43) (−0.32; 1.82) (−0.87; 1.33)
2 1 + age + glucose tolerance 0.68 1.75 1.97 0.16 1.01 0.14
(−0.12; 1.48) (0.67; 2.82) (0.69; 3.24) (−0.85; 1.17) (−0.06; 2.08) (−0.96; 1.24)
3 2 + hypertension 0.65 1.54 1.64 0.06 0.99 −0.06
(−0.14; 1.43) (0.49; 2.58) (0.40; 2.88) (−0.95; 1.07) (−0.07; 2.05) (−1.15; 1.04)
4 3 + prior cardiovascular disease 0.62 1.28 1.63 −0.09 0.75 −0.14
(−0.16; 1.40) (0.22; 2.33) (0.41; 2.86) (−1.09; 0.91) (−0.31; 1.81) (−1.22; 0.94)
5 3 + (b = micro-) albuminuria 0.49 1.00 1.39 0.02 0.81 0.02
(−0.30; 1.29) (−0.09; 2.08) (0.16; 2.62) (−0.97; 1.01) (−0.23; 1.85) (−1.05; 1.09)
6 3 + homocysteine 0.68 1.31 1.51 −0.32 0.58 −0.63
(−0.13; 1.49) (0.16; 2.46) (0.26; 2.75) (−0.14; 0.76) (−0.52; 1.68) (−1.77; 0.51)
7a 2 + mean arterial pressure — 1.59 1.76 — — —
(0.56; 2.61) (0.54; 2.98)
7b 6a + carotid distensibility — 1.18 1.32 — — —
(0.14; 2.21) (0.12; 2.51)
7cb 6a + carotid-femoral transit time — 0.02 0.54 — — —
(−1.60; 1.64) (−1.25; 2.33)
7db 6a + carotid Distensibility + — – 0.12 — — —
carotid-femoral transit time (−1.66; 1.89)
Results are expressed as regression coefficients and their 95% CI. Serum creatinine level expressed per 5 lmol/L increase, Cockcroft-Gault and Modification of Diet
in Renal Disease (MDRD) formula expressed per 5 mL/min/1.73 m2 decrease.
aIn adjusted models (2 to 7), age was omitted, as this variable is included in the formula. Results were similar when model 4 was additionally adjusted for lipid profile,
smoking or waist-to-hip ratio.
bAdditionally adjusted for height; number of men = 151 as carotid-femoral transit time was available in a random subsample only.
Table 3. Gender-specific characteristics of left ventricular geometry according to glomerular filtration rate (GFR)
Mena Womena
Left ventricular geometry GFR ≥ 70 50 ≤ GFR < 70 GFR < 50 GFR ≥ 70 50 ≤ GFR < 70 GFR < 50
Normal geometry% 82.5 76.9 60.9 76.5 81.3 75.0
Concentric remodeling% 10.5 11.7 15.9 13.2 12.8 18.2
Eccentric hypertrophy% 1.8 6.9 10.1 5.9 2.7 6.8
Concentric hypertrophy% 5.3 4.5 13.0 4.4 3.1 —
Left ventricular geometric patterns within each category of GFR according to the Modification of Diet in Renal Diseae (MDRD) formula in mL/min/1.73 m2 (see
the Methods section).
aP value for linear-by-linear association = 0.002 in men and = 0.51 in women.
DISCUSSION
The present population-based study of renal function
and left ventricular structure had three main findings.
First, impairment of renal function was associated with
greater left ventricular EDD and PWT and IVS, which
together determine LVM and left ventricular geometry.
Second, because PWT and IVS were more closely re-
lated to each other in men than in women, impairment
of renal function was associated with significantly greater
LVM and abnormal left ventricular geometry only in men.
Third, the association between impairment of renal func-
tion and greater LVM in men was explained entirely by
a greater arterial stiffness in men with impaired renal
function.
In men, a decrease in MDRD-estimated GFR from
90 to 60 mL/min/1.73 m2 was associated with an 8.3 g/m2
greater LVM (i.e., a 9% increase as compared to the male
population mean). Greater LVM may increase the risk of
myocardial infarction, heart failure, ventricular arrhyth-
mia, and sudden death [7, 8, 40, 43], and may thus present
a link between mild impairment of renal function and
increased risk of CVD [1, 4, 6, 9]. However, additional
studies are required to directly test this hypothesis.
This population-based study extends previous inves-
tigations [44–50], most of which have been relatively
small [45–47], and/or have focused upon selected pop-
ulations[44, 48–50].
In contrast to previous studies [45–47], we found im-
paired renal function to be associated with greater LVM
in men but not in women. There may be two explanations
for this finding. First, we studied an elderly population,
and selective mortality of women with greater LVM may
have weakened the association between renal function
and LVM (“healthy survivor effect”). Indeed, a greater
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Table 4. Associations between glomerular filtration rate and left ventricular structure in men and women
Model Dependent variable Men Women
1 End diastolic diameter cm 0.012 (−0.017; 0.042) 0.010 (−0.020; 0.039)
2 Posterior wall thickness cm 0.014 (0.014; 0.024) 0.011 (0.001; 0.020)
3 Interventricular septum thickness cm 0.024 (0.014; 0.033) 0.017 (0.007; 0.027)
4 Relative wall thickness 0.007 (0.002; 0.011) 0.006 (0.001; 0.010)
Results are expressed as regression coefficients and their 95% CI per 5 mL/min/1.7 3 m2 decrease as estimated by the Modification of Diet in Renal Disease
(MDRD) formula (see the Methods section). All models adjusted for age, glucose tolerance, hypertension, prior cardiovascular disease, and (micro-) albuminuria.
LVM is thought to be more strongly associated with risk
of CVD in women than in men [33–35, 37, 51]. Second, we
observed a stronger correlation between PWT and IVS
in men than in women, in whom changes in cardiac struc-
ture thus seemed less coordinated. This apparent lack of
coordination may reflect a gender0000-specific cellular
and biochemical response to myocyte growth-promoting
stimuli [35, 51–53]. In this context, it must be emphasized
that the lack of an association between renal function
and LVM in women does not necessarily mean that the
cardiac changes associated with renal function impair-
ment in women are innocuous. In women with impaired
renal function, greater left ventricular end diastolic di-
ameter and PWT and IVS may increase risk of cardiac
events even without increasing LVM, but data on this iss-
sue are scarce/and this hypothesis needs further testing
[51, 54].
The association between mild renal insufficiency and
greater LVM in men was accounted for entirely by greater
arterial stiffness in men with mild renal insufficiency. The
most straightforward explanation for this finding is that
mild renal insufficiency increases arterial stiffness, which
in turn leads to an increase in LVM [14–17, 55–57]. In-
deed, there is much evidence in favor of this interpreta-
tion [4]. The important new finding in this study is that
this process seems to start very early in the course of renal
functional deterioration.
This study had several limitations. First, we cannot ex-
clude that some unmeasured variable confounded the
associations between renal function and left ventricular
structure (in other words, we can not exclude the possi-
bility that the increase in LVM and arterial stiffness with
deteriorating GFR is the consequence of an unknown
risk factor causing both). However, we extensively char-
acterized out population (Table 1), and we can reason-
ably exclude that variables typically associated with im-
paired renal function, such as hypertension, hyperinsu-
linemia, and glucose intolerance, confounded the results.
Second, our study was cross-sectional. Our inference that
impaired renal function increases arterial stiffness and
thus LVM is therefore uncertain. We cannot exclude that
some unmeasured variable simultaneously increases ar-
terial stiffness and LVM without these increases being
causally related, and longitudinal studies are required to
investigate this.
We conclude that, in a general elderly population, even
mild impairment of renal function is associated with ad-
verse changes in left ventricular structure. In men, but not
in women, this leads to greater LVM and abnormal left
ventricular geometry, processes that may be related to in-
creases in arterial stiffness. Importantly, such changes oc-
cur early in the process of renal functional deterioration.
Whether such changes can explain, in part, the increase
in cardiovascular risk in individuals with mildly impaired
renal function remains to be shown.
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